Format

Send to

Choose Destination
Expert Opin Ther Targets. 2012 Apr;16(4):395-406. doi: 10.1517/14728222.2012.669752. Epub 2012 Mar 23.

Targeting VEGF in lung cancer.

Author information

1
Stanford University, Stanford Cancer Center, CA, USA.

Abstract

INTRODUCTION:

VEGF promotes tumor angiogenesis and is an important target in various malignancies, including NSCLC.

AREAS COVERED:

Here, the authors review the data that led to the approval of bevacizumab, a monoclonal antibody against VEGF, in the treatment of lung cancer. The authors also review the key results from a number of Phase II and Phase III trials involving other anti-angiogenic agents being studied in NSCLC, including small-molecule tyrosine kinase inhibitors against the VEGF-receptor and vascular-disrupting agents (VDAs).

EXPERT OPINION:

Results from ongoing studies and the identification of reliable biomarkers remain critical goals in understanding the exact role of these anti-angiogenic agents in the treatment paradigm of NSCLC.

PMID:
22439677
DOI:
10.1517/14728222.2012.669752
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center